Myocardial infarct size. Part 2. Comparison of anti-infarct effects of beta-blockade, glucose-insulin-potassium, nitrates, and hyaluronidase.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D006943:Hyperglycemia / Q000150:complications; D007328:Insulin / Q000378:metabolism*; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D009566:Nitrates / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D011188:Potassium / Q000378:metabolism; D011433:Propranolol / Q000627:therapeutic use; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D007328:Insulin; D009566:Nitrates; D009599:Nitroprusside; D006493:Heparin; D011433:Propranolol; D006821:Hyaluronoglucosaminidase; D005996:Nitroglycerin; D005947:Glucose; D011188:Potassium